Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial

Kris V. Kowdley, Eric Lawitz, Israel Crespo, Tarek Hassanein, Mitchell N. Davis, Michael Demicco, David E. Bernstein, Nezam Afdhal, John M. Vierling, Stuart C. Gordon, Jane K. Anderson, Robert H. Hyland, Hadas Dvory-Sobol, Di An, Robert G. Hindes, Efsevia Albanis, William T. Symonds, M. Michelle Berrey, David R. Nelson, Ira M. Jacobson

Research output: Contribution to journalArticlepeer-review

239 Scopus citations

Fingerprint

Dive into the research topics of 'Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences